Novartis

Takeda sells Shire’s Xiidra, transfers 400 staffers to Novartis in $3.4B deal
Fierce Pharma
Thu, 05/9/19 - 11:11 am
Takeda
Shire
Novartis
M&A
Xiidra
dry eye disease
Novartis sees Saudi Arabia as promising market for producing its cancer drugs
Fierce Pharma
Thu, 05/9/19 - 11:04 am
Novartis
oncology
cancer
Saudi Arabia
Pushing hard for blockbuster returns, Novartis finds PhIII data to assert Mayzent boosts cognitive powers in MS patients
Endpoints
Thu, 05/9/19 - 10:43 am
Novartis
Mayzent
siponimod
multiple sclerosis
Novartis Considers Offer for Takeda Eye-Disease Assets
Bloomberg
Wed, 05/8/19 - 05:25 pm
Novartis
Takeda
Shire
eye disease
M&A
Roche, PTC post latest SMA data from their attempt to rival Spinraza, Zolgensma
Fierce Biotech
Tue, 05/7/19 - 10:19 am
Roche
PTC Therapeutics
spinal muscular atrophy
risdiplam
Novartis
Zolgensma
Biogen
Spinraza
New Zolgensma data suggest comparable efficacy to Spinraza — analysts
Endpoints
Mon, 05/6/19 - 09:52 pm
Novartis
FDA
spinal muscular atrophy
Zolgensma
AveXis
Biogen
Spinraza
FDA Raises Concerns With Novartis in Clinical Inspection
RAPS.org
Mon, 05/6/19 - 07:30 pm
Novartis
FDA
Mayzent
siponimod
clinical trials
multiple sclerosis
Novartis makes final Zolgensma pitch before FDA decision
BioPharma Dive
Sun, 05/5/19 - 06:51 pm
Novartis
gene therapy
Zolgensma
FDA
spinal muscular atrophy
SMA Moment: Will Gene Therapy Shift Treatment, Costs of Muscle Disease?
Xconomy
Thu, 05/2/19 - 11:00 am
gene therapy
SMA
spinal muscular atrophy
Novartis
Zolgensma
Can 'synthetic lethality' and deep experience propel this cancer-fighting biotech's $70M IPO?
Bizjournals
Tue, 04/30/19 - 09:37 am
Ideaya
Novartis
IPOs
cancer
How a Medicare Rule Change Could Bring CAR-T Stocks Back to Life
Motley Fool
Sat, 04/27/19 - 10:47 am
Gilead Sciences
Novartis
CMS
Medicare
CAR-T
Pharma Giant Novartis Eyes Better 2019 Profit And 3 New Blockbuster Hopefuls
Investors Business Daily
Wed, 04/24/19 - 12:10 pm
Novartis
earnings
Novartis mulling $1.5 mln-$5 mln price range for SMA gene therapy
Yahoo/Reuters
Wed, 04/24/19 - 12:02 pm
Novartis
Zolgensma
gene therapy
drug pricing
spinal muscular atrophy
Novartis Poaches GSK Veteran as New Sandoz CEO
BioSpace
Wed, 04/24/19 - 11:48 am
Novartis
Sandoz
generics
Pharma CEOs
Richard Saynor
GSK
Health-care earnings: ‘Medicare for all’ looms large
Marketwatch
Tue, 04/23/19 - 09:53 am
earnings
Biogen
Novartis
Anthem
Boston Scientific
CAR-T Drugmaker Poseida Snags $142 Million in Financing Led by Novartis
BioSpace
Mon, 04/22/19 - 10:12 am
Poseida Therapeutics
Novartis
CAR-T
Novartis' star gene therapy faces potential safety issue following a recent infant death in study
Endpoints
Sun, 04/21/19 - 12:23 am
Novartis
Zolgensma
SMA
With FDA decision near, Novartis bolsters SMA gene therapy case
Biopharma Dive
Wed, 04/17/19 - 09:57 am
Novartis
FDA
Zolgensma
spinal muscular atrophy
FDA accepts BLA for Novartis' AMD therapy
BioCentury
Mon, 04/15/19 - 11:31 pm
Novartis
FDA
wet age-related macular degeneration
brolucizumab
Manufacturing problems persist for Aurobindo, U.S.' second-largest generics producer
Fierce Pharma
Tue, 04/9/19 - 10:18 pm
Aurobindo
generics
Novartis
drug manufacturing

Pages